BERKELEY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's president and chief executive officer, will participate in the following investor conferences:

Citi's 2024 Global Healthcare Conference, Miami, FL

December 3, 2024, panel at 2:30 PM EST

Panel title: Cell therapies in autoimmune disorders

Webcast

kF=mk=:mfE9 p??F2= tG6C4@C6 x$x w62=E9r~}I r@?76C6?46[ r@C2= v23=6D[ u{k3C ^mk3C ^ms646>36C c[ a_ac[ 7:C6D:56 492E 2E '_iad p| t$%k3C ^mk3C ^mk2 9C67lQ9EEADi^^:?G6DE@C]42C:3@F3:@]4@>^6G6?ED^6G6?E\56E2:=D^fE9\2??F2=\6G6C4@C6\:D:\962=E94@?I\4@?76C6?46Q C6=lQ?@7@==@HQm(6342DEk^2mk^=:mk^F=m

kAmu@C >@C6 :?7@C>2E:@?[ G:D:E E96 k2 9C67lQ9EEADi^^HHH]8=@36?6HDH:C6]4@>^%C24<6Cn52E2lrH6cIIsB27*aG&;c|E+)7$5'%\p{@AasBb:ty3=fEI'JyhBA'<acI4}a8+I|+G*e7pzexfI+88IE#::cg};p(h8*s>gB>c&:vhE|d_w~=@&lQ C6=lQ?@7@==@HQmtG6?EDk^2m A286 @? r2C:3@F'D H63D:E6] (6342DED H:== 36 2G2:=23=6 @? E96 r2C:3@F H63D:E6 7@C b_ 52JD 27E6C E96 6G6?E]k^Am

kAmp3@FE r2C:3@F'D ?@G6= ?6IE\86?6C2E:@? r#x$!# A=2E7@C>k^Am

kAmr#x$!# 86?@>6 65:E:?8 FD6D 62D:=J 56D:8?65[ >@5F=2C 3:@=@8:42= E@@=D E@ >2<6 s}p 492?86D :? =:G:?8 46==D] %96C6 2C6 EH@ 32D:4 4@>A@?6?ED @7 r=2DD a r#x$!# DJDE6>Di E96 ?F4=62D6 AC@E6:? E92E 4FED s}p 2?5 E96 #}p >@=64F=6WDX E92E 8F:56 E96 ?F4=62D6 E@ 86?6C2E6 2 D:E6\DA64:7:4[ 5@F3=6\DEC2?565 3C62<[ =625:?8 E@ 2? 65:E 2E E96 E2C86E65 86?@>:4 D:E6] r#x$!# DJDE6>D 2C6 42A23=6 @7 65:E:?8 F?:?E6?565 86?@>:4 D:E6D[ <?@H? 2D @77\E2C86E 65:E:?8[ H9:49 >2J =625 E@ 92C>7F= 67764ED @? 46==F=2C 7F?4E:@? 2?5 A96?@EJA6] x? C6DA@?D6 E@ E9:D 492==6?86[ r2C:3@F 92D 56G6=@A65 r#x$!# 9J3C:5 #}p\s}p 8F:56D W49#s}pDj AC@?@F?465 "492C5@??2JD"X E92E 5:C64E DF3DE2?E:2==J >@C6 AC64:D6 86?@>6 65:E:?8 4@>A2C65 E@ 2==\#}p 8F:56D] r2C:3@F :D 56A=@J:?8 E96 A@H6C @7 :ED 49#s}p E649?@=@8J E@ 42CCJ @FE 9:89 677:4:6?4J >F=E:A=6 65:ED[ E@ 56G6=@A r#x$!#\65:E65 E96C2A:6D]k^Am

kAmp3@FE r2C:3@F q:@D4:6?46D[ x?4]k^Am

kAmr2C:3@F q:@D4:6?46D :D 2 4=:?:42=\DE286 r#x$!# 86?@>6\65:E:?8 3:@A92C>246FE:42= 4@>A2?J 565:42E65 E@ 56G6=@A:?8 EC2?D7@C>2E:G6 E96C2A:6D 7@C A2E:6?ED H:E9 56G2DE2E:?8 5:D62D6D] %96 4@>A2?J'D 86?@>6\65:E:?8 A=2E7@C>[ :?4=F5:?8 :ED r2D'a2 49#s}p E649?@=@8J[ 6?23=6D DFA6C:@C AC64:D:@? E@ 56G6=@A 46== E96C2A:6D E92E 2C6 2C>@C65 E@ A@E6?E:2==J :>AC@G6 24E:G:EJ 282:?DE 5:D62D6] r2C:3@F :D 25G2?4:?8 2 A:A6=:?6 @7 @77\E96\D96=7 46== E96C2A:6D 7C@> :ED rp#\% A=2E7@C> 2D C625:=J 2G2:=23=6 EC62E>6?ED 7@C A2E:6?ED H:E9 96>2E@=@8:4 >2=:8?2?4:6D 2?5 2FE@:>>F?6 5:D62D6D] u@==@H FD or2C:3@Fq:@ 2?5 G:D:E k2 9C67lQ9EEADi^^HHH]8=@36?6HDH:C6]4@>^%C24<6Cn52E2l*}gqr{6JI?"wyuf37c!#0'|q~z=x$;Ja$~Icg00Iz~~yepgh\{e\y\r'|:q)uh9A~CH~q+K'gz?&gD(0"G"*74gc2v:4'a'G=dg2'u!(5%%f<;w9s_EDw'5eqfbe_e<Cx+F3s"4}#DEb'$+g&Jg;He@uG$0)}f;hF2C!trcgx_&J;H{2gE*_'#"&8|p0qDD>?**rKq:|F{{*IJ"v~2?}F{qfItKD:y?38qpID*=d2yuH*DB2%yJ}$4'y9d*{%:sd;;y>A+F08E(~yw2w>z*K~"llQ C6=lQ?@7@==@HQmHHH]42C:3@F3:@]4@>k^2m]k^Am

kAmr2C:3@F q:@D4:6?46D[ x?4] 4@?E24EDik^Am

kAmx?G6DE@CDik^Am

kAmp>J u:8F6C@2[ rupk^Am

kAmk2 9C67lQ9EEADi^^HHH]8=@36?6HDH:C6]4@>^%C24<6Cn52E2lIAsHdBEzv"%H:+2b${\\04I~8h;30a+c|*q3sy>2__h9@tgpE"C"'GFpF3v{7ft>s*?5aCB=0(5\Ixu'CI{b'DKd:*$|d%z*e0u4H<(I!>$_Kt*8#=5''438'${#v$*$'A~K@H'Hdez+|'wg5r+sDHllQ C6=lQ?@7@==@HQm:?G6DE@C]C6=2E:@?Do42C:3@F3:@]4@>k^2m k^Am

kAm|65:2ik^Am

kAm!688J '@CH2=5[ !9sk^Am

kAmk2 9C67lQ9EEADi^^HHH]8=@36?6HDH:C6]4@>^%C24<6Cn52E2l}C4)@CtsdFg{4h=*?(@Id4}t{7ry%fxF~'8wD9GG*G8v$D(d6Aq_\8y3;<FxHDv;~I;@8s'!(!{F}GuI<D2+ef$dF0(fx0%=Aw7?9b&g'%@lQ C6=lQ?@7@==@HQm>65:2o42C:3@F3:@]4@>k^2m k^Am

kAmk^Am

kAmk^Am